



Osiris Therapeutics to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound Healing Society Spring Conference

April 24, 2018

Experts to host a variety of presentations from April 25 – April 29, 2018, in Charlotte, North Carolina

COLUMBIA, Maryland, April 24, 2018 (GLOBE NEWSWIRE) -- [Osiris Therapeutics, Inc.](#) (OTC Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS) Spring Conference, the nation's largest interdisciplinary joint wound care event within the clinical field.

Osiris will be presenting a total of seven abstracts, including two clinical studies and five scientific studies. The clinical studies demonstrate positive outcomes of Osiris's placental membrane product, Grafix®. The scientific studies include the characterization and properties of placental membranes and umbilical cord tissues. Key presentations and events are highlighted below.

Dr. Mathew Regulski, DPM, will be presenting an abstract entitled, "Open-Label Extension Phase Of The Chronic Diabetic Foot Ulcer Multicenter, Controlled, Randomized Clinical Trial Confirms Benefits Of Viable Cryopreserved Placental Membrane For Wound Closure And Reduction Of Adverse Events", on Saturday, April 28 at 3:30 pm (SAWC Oral Abstract #43.2). This study reports Grafix outcomes in the single-arm open-label extension phase of the Grafix multicenter controlled randomized clinical trial for chronic diabetic foot ulcer (DFU) management (Lavery et al., *Int Wound J*, 2014, 11(5): 554-560). Results show that 65.4% of patients closed their wounds in a median of 34 days and three visits. There were fewer adverse events (AEs) (24 Grafix vs 52 standard wound care (SWC)) and wound-related infections (5 Grafix vs 12 SWC) during vCPM applications compared to the number of AEs for the same patients. These results confirm the benefits of Grafix with SWC over SWC alone for chronic DFUs previously reported for the blinded randomized phase of the trial which directly relate to lower healthcare costs. This abstract won the third place award and has been selected for the podium presentation by the Abstract Selection Committee of the 31st Annual Symposium on Advanced Wound Care & Wound Healing Society Meeting. Results of this study will also be presented at the poster session on Friday, April 27 at 7:15 pm in Exhibit Hall C1 (SAWC Poster #CR-022).

Dr. Kathrine Raspovic, DPM, will be presenting a poster entitled, "Effectiveness Of Viable Cryopreserved Placental Membranes For Management Of Diabetic Foot Ulcers In A Real World Setting", on Friday, April 27 at 7:15 pm in Exhibit Hall C1 (SAWC Poster #CR-040). In this retrospective study, the effectiveness of Grafix for the management of DFUs using certain participating customer data from Net Health's WoundExpert® electronic health records (EHR) database (Net Health, Pittsburgh, PA) was evaluated. Analysis showed that 59.4% of wounds achieved complete closure with Grafix as an adjunct to standard of care. This is consistent with 62% DFU closure reported previously in the Grafix (vCPM) RCT for chronic DFU management (Lavery et al., *Int Wound J*, 2014, 11(5): 554-560). Analysis of vCPM clinical outcomes in the real world setting supports vCPM benefits for DFU management and supplements the RCT data.

Dr. Charles Ananian, DPM, will be presenting a lecture entitled, "Clinical and Scientific Advances in the Use of Placental Membranes", on Thursday, April 26, at 12:00 pm. This lecture will provide comprehensive scientific and clinical evidence of viable cryopreserved placental membranes for use in the management of acute and chronic wounds.

Two scientific studies will be presented by Osiris scientists. A WHS Abstract (#H2.05), entitled, "Viable Cryopreserved Umbilical Tissue (vCUT) Inhibits Bacterial Growth In A Subcutaneous Rat Infection Model", will be presented on Thursday, April 26, at the WHS Session H2 (Infection and Biofilms) at 4:55 pm. This podium presentation summarizes the results of *in vivo* evaluation of viable cryopreserved umbilical tissue in a subcutaneous infection rat model that show inhibition of *E.Coli* and *S. Aureus* bacterial growth in the presence of vCUT. Results will also be presented at the poster session on Friday, April 27 at 7:15 pm in Exhibit Hall C1 (WHS Poster #P.IRD6).

Another scientific study entitled, "Viable Cryopreserved Umbilical Tissue (vCUT) Barrier Reduces Post-Operative Adhesions In A Rabbit Abdominal Adhesion Model", (#K2.03) will be presented at WHS Session K2 (Chronic Wounds and Inflammation) on Friday, April 27 at 2:35pm. The study demonstrates reduction of post-surgical inflammation and adhesions when vCUT is used as a barrier. vCUT structural and biomechanical properties are also described. In addition to the oral presentation, results of this study will be discussed at the poster session on Friday, April 27 at 7:15pm in Exhibit Hall C1 (WHS Poster # P.IRD1). The WHS abstract review committee selected both scientific studies for the WHS Industrial Research & Development Poster Award Competition.

The complete list of scientific and clinical abstracts includes:

WHS Abstract – selected for the podium presentation and WHS Industrial Research & Development Poster Award Competition

"Viable Cryopreserved Umbilical Tissue (vCUT) Inhibits Bacterial Growth In A Subcutaneous Rat Infection Model" (Oral Abstract #H2.05, WHS Session H2 (Infection and Biofilms), Room 207A, Thursday, April 26, at 4:55 pm; Poster #P.IRD6, Poster Gala/Awards Session, Room: Hall C1, Friday, April 27, 2018, 7:15 - 8:45 pm)

WHS Abstract – selected for the podium presentation and WHS Industrial Research & Development Poster Award Competition

"Viable Cryopreserved Umbilical Tissue (vCUT) Barrier Reduces Post-Operative Adhesions In A Rabbit Abdominal Adhesion Model" (Oral Abstract #K2.03, WHS Session K2 (Chronic Wounds and Inflammation), Room 207A, Friday, April 27, at 2:35 pm; Poster #P.IRD1, Poster Gala/Awards Session, Room: Hall C1, Friday, April 27, 2018, 7:15 - 8:45 pm)

SAWC Third Place Oral Abstract Winner– selected for the podium presentation

"Open-Label Extension Phase Of The Chronic Diabetic Foot Ulcer Multicenter, Controlled, Randomized Clinical Trial Confirms Benefits Of Viable

Cryopreserved Placental Membrane For Wound Closure And Reduction Of Adverse Events” (Oral Abstract #43.2, SAWC Session, Saturday, April 28, at 3:30 pm; SAWC poster #CR-022, Poster Gala/Awards Session, Room: Hall C1, Friday, April 27, 2018, 7:15 - 8:45 pm)

“Assessment Of Human Amniotic Tissue Cell Viability” (WHS Poster #P.BIO05, Poster Gala/Awards Session, Room: Hall C1, Friday, April 27, 2018, 7:15 - 8:45 pm)

“Structural Properties Of Viable Lyophilized Placental Tissues” (WHS Poster #P.BIO02 , Poster Gala/Awards Session, Room: Hall C1, Friday, April 27, 2018, 7:15 - 8:45 pm)

“Human Cryopreserved Placental Tissues Inhibit Wound Associated Bacteria Biofilm Formation” (WHS Poster #P.IB01, Poster Gala/Awards Session, Room: Hall C1, Friday, April 27, 2018, 7:15 - 8:45 pm)

“Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting” (SAWC poster #CR-040, Poster Gala/Awards Session, Room: Hall C1, Friday, April 27, 2018, 7:15 - 8:45 pm)

Osiris Therapeutics will also be exhibiting at the [Symposium on Advanced Wound Care](#) and Wound Healing Society Meeting at booth 915. The event runs from April 25 through April 29, 2018 at the **Charlotte Convention Center**, Charlotte, North Carolina.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. We have achieved commercial success with products in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix, BIO⁴ (available exclusively through Stryker Corporation) and Cartiform (available exclusively through Arthrex, Inc.). We continue to advance our research and development by focusing on innovation in regenerative medicine, including the development of bioengineered stem cell and tissue based products. Osiris®, Grafix®, Grafix CORE®, Grafix PRIME®, Grafix XC®, Stravix®, Cartiform®, and Prestige™ are our trademarks. BIO4® is a trademark of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation. More information can be found on the Company’s website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

Statements herein relating to the future of Osiris Therapeutics, Inc. and the ongoing research and development of our products are forward-looking statements. Osiris Therapeutics, Inc. cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Osiris Therapeutics Inc. Annual Report on Form 10-K for the years ended December 31, 2017, 2016 and 2015 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Examples of forward-looking statements may include, without limitation, statements regarding the potential uses of Prestige™ Lyotechnology. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

For additional information, please contact:

Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
OsirisPR@Osiris.com

 [Primary Logo](#)

Source: Osiris Therapeutics, Inc.